---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027549"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:22:25.469917+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q2 net income $4.6M, product sales +175% YoY; full-year revenue guidance raised to ~$30M

## Summary
- Net income of $4.6M ($0.18 per share) vs net loss of $1.6M a year ago.
- Product sales and royalty revenue of $6.5M, up 175% YoY and 22% sequentially; 10th straight quarter of growth.
- Total Q2 revenue of $12.0M, including $5.5M from sale of neurology royalty interests.
- Raised full-year revenue guidance to approximately $30M; launched Betaine Anhydrous in May.
- ET-400 NDA submission on track for Q4 2023; cash $21.6M at quarter-end.

## SEC filing metadata
- accession: 0001493152-23-027549
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027549
- JSON: https://secwatch.observer/filing/0001493152-23-027549.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027549.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported full year 2023 results: revenue approximately $30 million in total revenue this year. Guidance raised.
  - Period: full year 2023
  - Revenue: approximately $30 million in total revenue this year
  - Guidance: raised
  - Result: guidance update
  source text: Given our strong performance through the first half of the year, we have increased our revenue expectation and now anticipate reaching approximately $30 million in total revenue this year," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $12.0 million, net income $4.6 million, EPS $0.18 per basic and diluted share.
  - Period: second quarter ended June 30, 2023
  - Revenue: $12.0 million
  - Net income: $4.6 million
  - EPS: $0.18 per basic and diluted share
  - Result: reported results
  source text: Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period. Net sales included $5.5 million of licensing payments received during the quarter related to the sale of Eton’s neurology product royalties and milestones to Azurity Pharmaceuticals, compared to $5.0 million of licensing revenue in the prior year period related to the sale of multiple hospital products to Dr. Reddy’s. Product sales and royalty revenue were $6.5 million for the second quarter of 2023 compared with $2.4 million in the prior year period, an increase of 175% over the prior year period and 22% over the first quarter of 2023. The year-over-year increase in product sales and royalty revenue was primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid tablets. Gross Profit : Gross profit for the second quarter of 2023 was $9.7 million compared with $4.6 million in the prior year period. The growth was driven by the sale of the Company’s neurolo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.